Assertio Holdings (ASRT) - Long-Term Liabilities to Capital

Assertio - graphic logo of issuer ASRT

Geopolitical tensions are limiting the export of neurological drugs and access to foreign substances. The ratio of long-term debt to equity allows for a risk assessment, where 0.52 serves as the base parameter value. Demand for analgesics remains stable, ensuring the business's resilience to economic cycles. Meanwhile, Assertio Holdings, Inc. (ASRT) logistics hubs and packaging capacities are operating without downtime.

assertiotx.com (ASRT): Long-Term Debt to Equity from 07/04/2022 to 06/27/2026
Original product of Assertio Holdings

Earnings volatility at Assertio Holdings, Inc. (ASRT) driven by neurology patent risks necessitates strict control over the liability structure. This ratio correlates liabilities with maturities exceeding one year against equity. This allows for an assessment of the business's dependence on external borrowing amidst unstable cash flows. Reducing leverage ensures the company's survival during periods of declining demand. The trend of the long-term financial stability indicator regarding debt determines the issuer's margin of safety.

Analysis of competing companies

Long-Term Debt to Capital Ratio BIIB (Biogen Inc)|Long-Term Debt to Capital NBIX|RGC - Long-Term Liabilities to Capital|Axsome Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital acadia-pharm.com ACAD|XENE - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Catalyst Corp (CPRX)|DNLI (Denali Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital harmonybiosciences.com|Long-Term Debt to Equity Biohaven (BHVN)|Ratio of Long-Term Indebtedness to Capital Amylyx Pharmaceuticals Inc|Long-Term Debt to Equity Trevi Pharma TRVI|Ratio of Long-Term Indebtedness to Capital Praxis Corp (PRAX)|Anavex Life Sciences - Long-Term Debt to Capital|Long-Term Liabilities to Capital ceribell.com|Prothena Corp (PRTA) - Long-Term Debt to Equity|Alector - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio ANNX|OMER (Omeros Corp.) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital NGNE|Ratio of Long-Term Indebtedness to Capital acimmune.com|Long-Term Debt to Equity Voyager Therapeutics, Inc. VYGR|Neumora (NMRA) - Long-Term Liabilities to Capital|SCLX: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient TVGN (Tevogen Bio Inc.)|ACOG: Long-Term Debt to Capital|cogrx.com - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Inhibikase Therapeutics, Inc.|Long-Term Liabilities to Capital Cassava Sciences Inc SAVA|Long-Term Debt to Equity Coya Therapeutics, Inc. (COYA)|Long-Term Debt to Equity VTGN (vistagen.com)|Long-Term Debt to Capital OVID (Ovid Therapeutics)|ABOS: Long-Term Debt to Capital Ratio|CervoMed - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Alterity Therapeutics ATHE|clene.com (CLNN) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio PEPG|JUNS (Jupiter Neurosciences Inc) - Long-Term Debt to Capital|RLMD - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Annovis Bio (ANVS)|Ratio of Long-Term Indebtedness to Capital gracetx.com|Firefly Neuroscience Inc - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient KLTO|NeuroSense Therapeutics, Ltd. - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital revivapharma.com RVPH|metaviatx.com (MTVA) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio NRXS|HSDT (Helius Medical Technologies, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Passage Bio Corp (PASG)|Long-Term Debt to Equity Ratio NEUP (Neuphoria Therapeutics Inc.)|Ratio of Long-Term Indebtedness to Capital minervaneurosciences.com|Long-Term Debt to Capital ATHA (Athira Pharma)|Long-Term Debt to Capital Addex Therapeutics Ltd. ADXN|ALZN - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Cyclerion Therapeutics CYCN|protagenic.com (PTIX) - Long-Term Debt to Equity|Pasithea Therapeutics Corp. - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio CRGT|ATXI (Avenue Therapeutics Inc.) - Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Brainstorm Cell Therapeutics, Inc. (BCLI)|Cara Therapeutics Inc - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital CHRO (Chromocell Therapeutics)|Eliem Therapeutics, Inc. (ELYM) - Long-Term Liabilities to Capital|ITCI: Long-Term Debt to Equity Ratio|LBPH - Long-Term Debt to Capital|Marinus (MRNS) - Long-Term Debt to Equity|NKGen Biotech Corp - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity NeuroBo Pharmaceuticals|Long-Term Liabilities to Capital sagerx.com SAGE|Long-Term Debt to Capital SNPX|Long-Term Debt to Capital Trevena Inc. (TRVN)|Long-Term Debt to Equity Vigil Neuroscience, Inc. VIGL|Ratio of Long-Term Indebtedness to Capital Anew Medical Inc. (WENA)|CERE - Long-Term Debt to Equity